IL237985B - Humanized immunobinder capable of binding to an antigen of interest - Google Patents
Humanized immunobinder capable of binding to an antigen of interestInfo
- Publication number
- IL237985B IL237985B IL237985A IL23798515A IL237985B IL 237985 B IL237985 B IL 237985B IL 237985 A IL237985 A IL 237985A IL 23798515 A IL23798515 A IL 23798515A IL 237985 B IL237985 B IL 237985B
- Authority
- IL
- Israel
- Prior art keywords
- antigen
- interest
- binding
- humanized immunobinder
- humanized
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5052—Cells of the immune system involving B-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15510509P | 2009-02-24 | 2009-02-24 | |
US15504109P | 2009-02-24 | 2009-02-24 | |
CH8322009 | 2009-06-02 | ||
PCT/CH2009/000222 WO2009155726A2 (en) | 2008-06-25 | 2009-06-25 | Humanization of rabbit antibodies using a universal antibody framework |
PCT/CH2010/000044 WO2010096941A1 (en) | 2009-02-24 | 2010-02-22 | Methods for identifying immunobinders of cell-surface antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
IL237985B true IL237985B (en) | 2018-12-31 |
Family
ID=48917567
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL226955A IL226955A (en) | 2009-02-24 | 2013-06-13 | Methods for identifying a b-cell clone that specifically binds to an antigen of interest, methods for producing an immunobinder and immunobinders produced by said methods |
IL226956A IL226956A (en) | 2009-02-24 | 2013-06-13 | Methods for identifying an immunobinder that specifically binds to an antigen of interest |
IL237985A IL237985B (en) | 2009-02-24 | 2015-03-26 | Humanized immunobinder capable of binding to an antigen of interest |
IL26315818A IL263158B (en) | 2009-02-24 | 2018-11-20 | Methods for identifying immunobinders of cell-surface antigens |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL226955A IL226955A (en) | 2009-02-24 | 2013-06-13 | Methods for identifying a b-cell clone that specifically binds to an antigen of interest, methods for producing an immunobinder and immunobinders produced by said methods |
IL226956A IL226956A (en) | 2009-02-24 | 2013-06-13 | Methods for identifying an immunobinder that specifically binds to an antigen of interest |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL26315818A IL263158B (en) | 2009-02-24 | 2018-11-20 | Methods for identifying immunobinders of cell-surface antigens |
Country Status (12)
Country | Link |
---|---|
JP (3) | JP6161655B2 (en) |
KR (4) | KR101817279B1 (en) |
CN (1) | CN105116138A (en) |
BR (1) | BRPI1005398A2 (en) |
CL (1) | CL2011001453A1 (en) |
ES (1) | ES2618181T3 (en) |
IL (4) | IL226955A (en) |
MX (1) | MX352922B (en) |
PH (1) | PH12014502468B1 (en) |
RU (2) | RU2577965C2 (en) |
SG (3) | SG10201708233VA (en) |
ZA (1) | ZA201103125B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110016462B (en) * | 2019-02-20 | 2020-04-24 | 优睿赛思(武汉)生物科技有限公司 | Method for efficiently separating single antigen-specific B lymphocytes from spleen cells |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63253098A (en) * | 1987-04-10 | 1988-10-20 | Ube Ind Ltd | Monoclonal antibody against human antibody, its production and use thereof |
IL91948A (en) | 1988-10-26 | 1994-05-30 | Immunomedics | Removal of immunoreactive components from a sample |
US5417972A (en) * | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
KR0119909B1 (en) * | 1993-10-05 | 1997-10-20 | 김은영 | Immunology measurement using flow cytometer |
EP1709970A1 (en) * | 1995-04-27 | 2006-10-11 | Abgenix, Inc. | Human antibodies against EGFR, derived from immunized xenomice |
ATE253593T1 (en) * | 1996-07-16 | 2003-11-15 | Plueckthun Andreas Prof Dr | IMMUNOGLOBULIN SUPERFAMILY DOMAINS AND FRAGMENTS WITH INCREASED SOLUBILITY |
DK1506236T3 (en) * | 2002-05-22 | 2013-03-04 | Esbatech A Novartis Co Llc | IMMUNGLOBULIN FRAMEWORKS PROVIDING IMPROVED STABILITY IN THE INTRACELLULAR ENVIRONMENT AND PROCEDURES FOR IDENTIFICATION THEREOF |
CN1396182A (en) * | 2002-07-31 | 2003-02-12 | 陕西超英生物医学研究开发有限公司 | Human monoclonal antibody of human endophloeodal growth factor receptor 2 protein and its preparing process |
AU2003264009A1 (en) | 2002-08-15 | 2004-03-03 | Epitomics, Inc. | Humanized rabbit antibodies |
CA2505924A1 (en) * | 2002-11-13 | 2004-05-27 | Micromet Ag | Method for identifying antigen specific b cells |
JP4336812B2 (en) * | 2003-03-07 | 2009-09-30 | 博夫 岩田 | Analytical method for rapid identification of surface antigens expressed in cells |
US20070087331A1 (en) * | 2003-05-15 | 2007-04-19 | Cytos Biotechnology Ag | Selection of b cells with specificity if interest: method of preparation and use |
CN100415765C (en) | 2003-08-07 | 2008-09-03 | 宜康公司 | Methods for humanizing rabbit monoclonal antibodies |
CA2655511C (en) * | 2005-07-01 | 2017-03-21 | John Schrader | Methods of isolating cells and generating monoclonal antibodies |
US20070134249A1 (en) | 2005-12-08 | 2007-06-14 | Genitope Corporation | Combination therapy and antibody panels |
KR101363695B1 (en) * | 2005-12-28 | 2014-02-14 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | An antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved |
MY159787A (en) * | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
WO2008004834A1 (en) * | 2006-07-06 | 2008-01-10 | Isu Abxis Co., Ltd | Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor |
-
2010
- 2010-02-22 CN CN201510261116.5A patent/CN105116138A/en active Pending
- 2010-02-22 SG SG10201708233VA patent/SG10201708233VA/en unknown
- 2010-02-22 SG SG2014014864A patent/SG2014014864A/en unknown
- 2010-02-22 MX MX2015017453A patent/MX352922B/en unknown
- 2010-02-22 KR KR1020167035683A patent/KR101817279B1/en active IP Right Grant
- 2010-02-22 SG SG10201408247SA patent/SG10201408247SA/en unknown
- 2010-02-22 KR KR1020167003693A patent/KR101689791B1/en active IP Right Grant
- 2010-02-22 ES ES10705086.6T patent/ES2618181T3/en active Active
- 2010-02-22 BR BRPI1005398-0A patent/BRPI1005398A2/en not_active Application Discontinuation
- 2010-02-22 KR KR1020197005221A patent/KR102059866B1/en active IP Right Grant
- 2010-02-22 KR KR1020187000320A patent/KR20180005752A/en active Application Filing
- 2010-02-22 RU RU2011124039/10A patent/RU2577965C2/en active
-
2011
- 2011-04-28 ZA ZA2011/03125A patent/ZA201103125B/en unknown
- 2011-06-15 CL CL2011001453A patent/CL2011001453A1/en unknown
-
2013
- 2013-06-13 IL IL226955A patent/IL226955A/en active IP Right Grant
- 2013-06-13 IL IL226956A patent/IL226956A/en active IP Right Grant
-
2014
- 2014-11-05 PH PH12014502468A patent/PH12014502468B1/en unknown
-
2015
- 2015-03-26 IL IL237985A patent/IL237985B/en active IP Right Grant
- 2015-05-19 JP JP2015101581A patent/JP6161655B2/en active Active
-
2017
- 2017-04-28 JP JP2017090650A patent/JP6604989B2/en not_active Expired - Fee Related
- 2017-10-09 RU RU2017135831A patent/RU2017135831A/en not_active Application Discontinuation
-
2018
- 2018-09-14 JP JP2018172287A patent/JP2018196395A/en active Pending
- 2018-11-20 IL IL26315818A patent/IL263158B/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1900048I1 (en) | Anti-il-23 antibodies | |
ZA201200732B (en) | Fully human antibodies to btla | |
ZA201208906B (en) | Humanised antigen binding proteins to myostatin6 | |
ZA201204459B (en) | Formulations of antibody | |
IL220404A (en) | Humanized antibodies | |
IL218724A0 (en) | Endoglin antibodies | |
EP2658970A4 (en) | Express humanization of antibodies | |
HK1217711A1 (en) | Antibodies specific to cadherin-17 -17 | |
ZA201209390B (en) | Comparison of protein samples | |
ZA201106480B (en) | Humanized anti-cd19 antibody formulations | |
IL217919A0 (en) | Humanized anti-cdcp1 antibodies | |
IL214779A0 (en) | Fully human antibodies specific to cadm1 | |
EP2542258A4 (en) | Monoclonal antibodies directed to cd52 | |
EP2650367A4 (en) | Human monoclonal antibody | |
EP2542262A4 (en) | Monoclonal antibodies directed to cd20 | |
EP2383336A4 (en) | Peptide capable of binding to immunoglobulin | |
EP2478364A4 (en) | Detection of antibodies | |
IL237985B (en) | Humanized immunobinder capable of binding to an antigen of interest | |
WO2011116014A9 (en) | Humanized antibodies to labyrinthin and uses thereof | |
EP2623512A4 (en) | Peptide capable of binding to immunoglobulin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed |